Regarding the CMV, nowadays that we are entering also into the possibility of having prophylaxis for our patients in clinical practice, I think that it will be really useful to really make a good stratification of the risk of the patient because we know that the duration of the prophylaxis can be different and trying also to have a better understanding of the risk of our patient...
Regarding the CMV, nowadays that we are entering also into the possibility of having prophylaxis for our patients in clinical practice, I think that it will be really useful to really make a good stratification of the risk of the patient because we know that the duration of the prophylaxis can be different and trying also to have a better understanding of the risk of our patient. Checking also the CMV-specific immunity can be really of interest in this context because we know that there are several risk factors related to the type of transplant that we are performing, but delayed T-cell recovery is also another important aspect in the patient risk stratification. And having the possibility for the future to have a standardized and harmonized test to have more insight into the CMV immunity of our patients will be really helpful to have also a better management of CMV infection in the context of the transplant community.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
